GOSS supply chain intelligence for Gossamer Bio, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Gossamer Bio, Inc. (GOSS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| IKT | Inhibikase Therapeutics, Inc. | 72% | Reciprocal relationship from IKT graph: Reciprocal relationship from GOSS graph: Reciprocal relationship from IKT graph: file of our products following approval; • effective competition with other th… |
| KROS | Keros Therapeutics, Inc. | 72% | Reciprocal relationship from KROS graph: Reciprocal relationship from GOSS graph: Reciprocal relationship from KROS graph: Reciprocal relationship from GOSS graph: Reciprocal relationship from KROS g… |
| LQDA | Liquidia Corporation | 72% | Reciprocal relationship from LQDA graph: Reciprocal relationship from GOSS graph: Reciprocal relationship from LQDA graph: -offs related to Sandoz’s inability to sell Treprostinil Injection, includin… |
| XOMA | XOMA Royalty Corporation | 72% | Reciprocal relationship from XOMA graph: million. Receipts pursuant to the Daré RPAs were negligible in 2025. DSUVIA - Talphera Commercial Payment Purchase Agreement In January 2024, we acquired an e… |
| XOMAP | XOMA Royalty Corporation | 72% | Reciprocal relationship from XOMAP graph: Reciprocal relationship from GOSS graph: Reciprocal relationship from XOMAP graph: Reciprocal relationship from GOSS graph: Reciprocal relationship from XOMA… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CHIESI | CHIESI | 92% | During the three months ended March 31, 2026, Chiesi was the Company's principal customer, accounting for 100 % of its revenue. |
| LQDA | Liquidia Corporation | 72% | Reciprocal relationship from LQDA graph: -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injection expires prior to sale. Currently, Trepr… |
| XOMAP | XOMA Royalty Corporation | 72% | Reciprocal relationship from XOMAP graph: Reciprocal relationship from GOSS graph: Reciprocal relationship from XOMAP graph: Reciprocal relationship from GOSS graph: e 2027 Notes. When the 2027 Notes… |
| XOMAP | XOMA Royalty Corporation | 72% | e 2027 Notes. When the 2027 Notes become convertible within 12 months of the balance sheet date, the carrying value of the 2027 Notes will be reclassified to short-term. The Company recorded $ 0.4 mi… |
| FSG-BIO-INC | FSG-BIO-INC | 62% | erm convertible senior notes 198,763 198,508 Operating lease liabilities - long-term 3,213 3,460 Long-term contract liabilities 31,900 29,606 Total liabilities 290,382 295,009 Commitments and conting… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| GOSS-DEBT | Debt stack $11.6M | 90% | Market cache reports total debt of $11.6M. |
| GOSS-DEBT-4765 | Warrants outstanding: 32467360 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| GOSS-DEBT-4766 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2022-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| GOSS-OWNER-PALO-ALTO-INVESTORS-LP | Palo Alto Investors Lp | 95% | 13F/ownership overlay lists Palo Alto Investors Lp; shares held 5,464,349; ownership 2.36%; value $12.7M; as of 2025-09-30. |
| GOSS-OWNER-NEA-MANAGEMENT-COMPANY-LLC | NEA Management Company, LLC | 95% | 13F/ownership overlay lists NEA Management Company, LLC; shares held 18,093,034; ownership 7.82%; value $42.0M; as of 2025-09-30. |
| GOSS-OWNER-HHLR-ADVISORS-LTD | HHLR Advisors, LTD | 95% | 13F/ownership overlay lists HHLR Advisors, LTD; shares held 4,974,041; ownership 2.15%; value $11.5M; as of 2025-09-30. |
| GOSS-OWNER-683-CAPITAL-MANAGEMENT-LLC | 683 Capital Management LLC | 95% | 13F/ownership overlay lists 683 Capital Management LLC; shares held 5,059,200; ownership 2.19%; value $11.7M; as of 2025-09-30. |
| GOSS-OWNER-ARCH-VENTURE-MANAGEMENT-LLC | Arch Venture Management, Llc | 95% | 13F/ownership overlay lists Arch Venture Management, Llc; shares held 8,055,916; ownership 3.48%; value $18.7M; as of 2025-09-30. |
| GOSS-OWNER-BLACKROCK-INC | Blackrock Inc. | 95% | 13F/ownership overlay lists Blackrock Inc.; shares held 13,846,054; ownership 5.98%; value $32.1M; as of 2025-09-30. |
| GOSS-OWNER-OCTAGON-CAPITAL-ADVISORS-LP | Octagon Capital Advisors LP | 95% | 13F/ownership overlay lists Octagon Capital Advisors LP; shares held 17,050,000; ownership 7.37%; value $39.6M; as of 2025-09-30. |
| GOSS-OWNER-SIREN-L-L-C | Siren, L.L.C. | 95% | 13F/ownership overlay lists Siren, L.L.C.; shares held 5,208,968; ownership 2.25%; value $12.1M; as of 2025-09-30. |
| GOSS-OWNER-SAMSARA-BIOCAPITAL-LLC | Samsara BioCapital, LLC | 95% | 13F/ownership overlay lists Samsara BioCapital, LLC; shares held 6,130,268; ownership 2.65%; value $14.2M; as of 2025-09-30. |
| GOSS-OWNER-VANGUARD-GROUP-INC | Vanguard Group Inc | 95% | 13F/ownership overlay lists Vanguard Group Inc; shares held 12,873,209; ownership 5.56%; value $29.9M; as of 2025-12-31. |
| GOSS-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 193 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| KROS | Keros Therapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| XOMAP | XOMA Royalty Corporation | 100.00 | 1 | ['customer', 'supplier'] |
| PLX | Protalix BioTherapeutics, Inc. | 100.00 | 2 | |
| JNJ | Johnson & Johnson | 100.00 | 2 | |
| XOMA | XOMA Royalty Corporation | 100.00 | 1 | ['supplier'] |
| LQDA | Liquidia Corporation | 100.00 | 1 | ['customer', 'supplier'] |
| IKT | Inhibikase Therapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| NVSEF | Novartis AG | 100.00 | 2 | |
| CHIESI | CHIESI | 63.48 | 1 | ['receiving'] |
| SNYNF | Sanofi | 50.00 | 2 | |
| DNLI | Denali Therapeutics Inc. | 50.00 | 2 | |
| IBIO | iBio, Inc. | 50.00 | 2 | |
| RZLT | Rezolute, Inc. | 50.00 | 2 | |
| LADX | LadRx Corporation | 50.00 | 2 | |
| ORANY | ORANGE | 50.00 | 2 | |
| TAK | Takeda Pharmaceutical Company Limited | 50.00 | 2 | |
| GSK | GSK plc | 50.00 | 2 | |
| SLDB | Solid Biosciences Inc. | 50.00 | 2 | |
| GILD | Gilead Sciences, Inc. | 50.00 | 2 | |
| GERN | Geron Corporation | 50.00 | 2 |